2016 Fiscal Year Final Research Report
Development of the specific adoptive immunotherapy for the invasive mucormycosis
| Project/Area Number |
26860791
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Shinshu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 接合菌症 / 養子免疫 / 接合菌血清診断 / 造血幹細胞移植 / 免疫不全症 |
|---|
| Outline of Final Research Achievements |
Although mucormycosis is a fatal complication in immunocompromised patients, there are no specific or useful serum biomarkers for diagnosing mucormycosis. A definitive diagnosis of mucormycosis is based on histopathological findings, molecular detection, and/or a positive culture in the affected tissue. We modified the qPCR assay (targeting Mucor/Rhizopus, Lichtheimia, and Rhizomucor) which Millon et al. had reported to indicate the absolute amount for the monitoring of activity of mucormycosis. In addition, we could purify Mucorales lysate and amplify fungus-specific T cells using aspergillus which were a representative filamentous fungi fungus and the dendritic cells.
|
| Free Research Field |
造血幹細胞移植
|
